Relmada Therapeutics Q2 EPS $(0.84) Beats $(0.90) Estimate
Portfolio Pulse from saritha@benzinga.com
Relmada Therapeutics reported Q2 losses of $(0.84) per share, beating the analyst consensus estimate of $(0.90) by 6.67%. This represents a 36.84% increase over losses from the same period last year.
August 08, 2023 | 8:02 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Relmada Therapeutics reported better than expected Q2 losses, which could positively impact the stock in the short term.
Relmada Therapeutics reported a smaller loss than expected for Q2, which is generally seen as positive news by investors. This could lead to an increase in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100